IMB-1018972

· Imbria Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for IMB-1018972, covering 2024-04-23 to 2025-11-10. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina [Phase 2]

See pricing